Conor MacKay
Stock Analyst at BMO Capital
(0.58)
# 4,272
Out of 5,053 analysts
10
Total ratings
n/a
Success rate
-15.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Conor MacKay
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Reiterated: Buy | $192 | $96.79 | +98.37% | 5 | Oct 12, 2026 | |
| TRVI Trevi Therapeutics | Reiterated: Buy | $36 | $12.29 | +192.92% | 2 | Oct 6, 2026 | |
| NAMS NewAmsterdam Pharma Company | Reiterated: Buy | $58 | $20.19 | +187.27% | 3 | Sep 21, 2026 |
Insmed
Oct 12, 2026
Reiterated: Buy
Price Target: $192
Current: $96.79
Upside: +98.37%
Trevi Therapeutics
Oct 6, 2026
Reiterated: Buy
Price Target: $36
Current: $12.29
Upside: +192.92%
NewAmsterdam Pharma Company
Sep 21, 2026
Reiterated: Buy
Price Target: $58
Current: $20.19
Upside: +187.27%